Abstract
The world population is growing older and age-related cognitive decline is becoming a burden of societal importance. D-serine is an endogenous amino acid that activates the co-agonist site of the NMDA-glutamate receptor, which is related to cognitive functions, such as learning and memory. Studies in aged rodents have shown a marked decrease in the levels of D-serine in brain regions such as the hippocampus, a key region for encoding memory. Exogenous administration of D-serine in rodents has demonstrated pro-cognitive effects in several brain functions, including memory and executive function. Further to animal studies, our group has observed an agerelated decrease in D-serine in the blood of healthy adults and elderly. The oral administration of D-serine induced significant improvement in executive function and spatial problem solving in elderly, some of the key cognitive domains affected by aging. In this review we propose the activation of the co-agonist site of NMDA receptors as a target to remediate features of the age-related cognitive decline. The cognitive effects of other agents targeting the co-agonist site of NMDA receptors are also discussed.
Keywords: Aging, NMDA receptor, D-serine, cognition, co-agonist site.
Current Pharmaceutical Design
Title:The Co-agonist Site of NMDA-glutamate Receptors: A Novel Therapeutic Target for Age-related Cognitive Decline
Volume: 20 Issue: 32
Author(s): Rogerio Panizzutti, Linda Scoriels and Marcos Avellar
Affiliation:
Keywords: Aging, NMDA receptor, D-serine, cognition, co-agonist site.
Abstract: The world population is growing older and age-related cognitive decline is becoming a burden of societal importance. D-serine is an endogenous amino acid that activates the co-agonist site of the NMDA-glutamate receptor, which is related to cognitive functions, such as learning and memory. Studies in aged rodents have shown a marked decrease in the levels of D-serine in brain regions such as the hippocampus, a key region for encoding memory. Exogenous administration of D-serine in rodents has demonstrated pro-cognitive effects in several brain functions, including memory and executive function. Further to animal studies, our group has observed an agerelated decrease in D-serine in the blood of healthy adults and elderly. The oral administration of D-serine induced significant improvement in executive function and spatial problem solving in elderly, some of the key cognitive domains affected by aging. In this review we propose the activation of the co-agonist site of NMDA receptors as a target to remediate features of the age-related cognitive decline. The cognitive effects of other agents targeting the co-agonist site of NMDA receptors are also discussed.
Export Options
About this article
Cite this article as:
Panizzutti Rogerio, Scoriels Linda and Avellar Marcos, The Co-agonist Site of NMDA-glutamate Receptors: A Novel Therapeutic Target for Age-related Cognitive Decline, Current Pharmaceutical Design 2014; 20 (32) . https://dx.doi.org/10.2174/1381612819666140110121139
DOI https://dx.doi.org/10.2174/1381612819666140110121139 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Human ABAD Inhibitors for Rescuing Aβ-Mediated Mitochondrial Dysfunction
Current Alzheimer Research Investigation on Risk Factor of Vascular Thrombotic Diseases in Patients with Obstructive Sleep Apnea Hypopnea Syndrome
Vascular Disease Prevention (Discontinued) Cholinesterase Inhibitors and Beyond
Current Alzheimer Research Drugs of Abuse-Induced Hyperthermia, Blood-Brain Barrier Dysfunction and Neurotoxicity: Neuroprotective Effects of a New Antioxidant Compound H-290/51
Current Pharmaceutical Design HIV-1 Entry Inhibitors: Classes, Applications and Factors Affecting Potency
Current HIV Research Interplay Between Cholesterol and Homocysteine in the Exacerbation of Amyloid-β Toxicity in Human Neuroblastoma Cells
CNS & Neurological Disorders - Drug Targets Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>
Current Hypertension Reviews Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry Patented In Vitro Blood-Brain Barrier Models in CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Evaluation of Blood Pressure Control using a New Arterial Stiffness Parameter, Cardio-ankle Vascular Index (CAVI)
Current Hypertension Reviews Environmental Enrichment as a Positive Behavioral Intervention Across the Lifespan
Current Neuropharmacology Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Kinases as Targets for Parkinson's Disease: From Genetics to Therapy
CNS & Neurological Disorders - Drug Targets Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets MTDL Design Strategy in the Context of Alzheimers Disease: From Lipocrine to Memoquin and Beyond
Current Pharmaceutical Design Dynamics of Nicotinic Acetylcholine Receptors and Receptor-Associated Proteins at the Vertebrate Neuromuscular Junction
Current Alzheimer Research Carotid and Vertebral Arterial Variations in Alzheimer's Disease
Current Alzheimer Research Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease
Current Alzheimer Research